Charles Schwab Investment Management Inc. Has $9.81 Million Position in Core Laboratories Inc. (NYSE:CLB)

Charles Schwab Investment Management Inc. reduced its position in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 11.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 529,522 shares of the oil and gas company's stock after selling 70,389 shares during the period. Charles Schwab Investment Management Inc. owned about 1.13% of Core Laboratories worth $9,812,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its position in shares of Core Laboratories by 8.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 27,450 shares of the oil and gas company's stock worth $469,000 after buying an additional 2,070 shares in the last quarter. SG Americas Securities LLC increased its holdings in Core Laboratories by 136.8% in the second quarter. SG Americas Securities LLC now owns 24,508 shares of the oil and gas company's stock valued at $497,000 after buying an additional 14,158 shares during the last quarter. Boston Trust Walden Corp raised its stake in Core Laboratories by 1.3% during the second quarter. Boston Trust Walden Corp now owns 729,760 shares of the oil and gas company's stock valued at $14,807,000 after buying an additional 9,468 shares in the last quarter. Exchange Capital Management Inc. bought a new position in Core Laboratories during the 2nd quarter worth approximately $553,000. Finally, Louisiana State Employees Retirement System increased its holdings in shares of Core Laboratories by 2.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 23,600 shares of the oil and gas company's stock valued at $479,000 after acquiring an additional 500 shares during the last quarter. 97.81% of the stock is owned by institutional investors and hedge funds.

Core Laboratories Price Performance

CLB stock traded up $0.43 during trading on Tuesday, hitting $19.82. The company had a trading volume of 138,273 shares, compared to its average volume of 412,229. Core Laboratories Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $25.13. The firm has a market capitalization of $930.55 million, a price-to-earnings ratio of 29.78, a P/E/G ratio of 1.30 and a beta of 2.35. The business has a 50 day moving average of $19.67 and a 200 day moving average of $19.65. The company has a current ratio of 2.48, a quick ratio of 1.79 and a debt-to-equity ratio of 0.55.

Core Laboratories (NYSE:CLB - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The oil and gas company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.21 by $0.04. The firm had revenue of $134.40 million for the quarter, compared to analysts' expectations of $134.16 million. Core Laboratories had a return on equity of 15.84% and a net margin of 5.83%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.22 earnings per share. As a group, research analysts predict that Core Laboratories Inc. will post 0.8 earnings per share for the current year.

Core Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Monday, November 4th were issued a $0.01 dividend. The ex-dividend date was Monday, November 4th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.20%. Core Laboratories's payout ratio is currently 6.15%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Core Laboratories from a "sell" rating to a "hold" rating in a research report on Thursday, November 7th. Citigroup cut their price target on Core Laboratories from $15.00 to $14.00 and set a "sell" rating on the stock in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating and three have issued a hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $17.00.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.